Get started
Author

Agnieszka Gierczak‐Pachulska

Observed names: AGNIESZKA GIERCZAK-PACHULSKA, Agnieszka Gierczak-Pachulska
Observed institution: Celon Pharma (Poland)
ORCID: 0009-0005-6508-5759
Observed ORCID: 0009-0005-6508-5759
OpenAlex ID: A5006485305
First‐in‐human study of CPL207280 , a novel G‐protein‐coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration
2024 · Katarzyna Bazydło‐Guzenda, Katarzyna Jarus‐Dziedzic, et al. · Diabetes Obesity and Metabolism · 5
PDF
761-P: Safety and Pharmacokinetic Study of GPR40 Agonist (CPL207280) after a Single Dose in Healthy Subjects
2021 · KATARZYNA BAZYDLO-GUZENDA, AGNIESZKA GIERCZAK-PACHULSKA, et al. · Diabetes · 4
First-in-human study of CPL’116 – a dual JAK/ROCK inhibitor – in healthy subjects
2025 · Piotr J. Rudzki, Katarzyna Jarus-Dziedzic, et al. · Frontiers in Pharmacology · 1
PDF
Relative Bioavailability of Ticagrelor from Hard Capsules and Film-Coated Tablets in Healthy Caucasian Volunteers
2025 · Michal Kaza, Agnieszka Gierczak-Pachulska, et al. · Acta Poloniae Pharmaceutica - Drug Research
PDF
Bioequivalence of Rivaroxaban Hard Capsules vs. Film-Coated Tablets in Healthy White Volunteers
2024 · Agnieszka Gierczak-Pachulska, Michał Kaza, et al. · Acta Poloniae Pharmaceutica - Drug Research
PDF
Works count: 5
Citation count: 10
H-index: 2
I10-index:
Year
Topic
Type